Improper use of medicines linked to 21,000 avoidable deaths each yearThursday’s Libération (bief p21 and website) reported that a healthcare professionals' association has alerted that misuse of medicine could be linked to more than 21,000 avoidable deaths each year in France.
GSK abandons race to acquire Pfizer’s OTC businessFriday’s Les Echos (website) reports on GlaxoSmithKline’s decision to withdraw from the bidding process for Pfizer’s Consumer healthcare business, 24 hours after Reckitt Benckiser pulled out (APMHE 57438).
AbbVie sinks on markets after Rova-T failureFriday’s Les Echos (website) writes that AbbVie’s market value fell by close to 15% after the company announced that it will stop the development of Rova-T in lung cancer (APMHE 57422).
A quarter of pharmacists recommend dangerous paracetamol dosesThursday’s Libération (brief p19), L’Humanité (brief p11) and 20 Minutes (brief p8) reported that one pharmacist in four in France recommends doses of paracetamol that are higher than safe levels.
Pharmacists ask to extend vaccination experimentMonday’s Les Echos (p3) reported that pharmacists’ union USPO has asked the government to extend an experiment allowing pharmacists to carry out vaccinations in two regions to the whole country.
Teva cuts half of its workforce in FranceAlso on Wednesday, Les Echos (p16) reported on Teva’s announcement that it will cut half of its workforce in France, with 248 out of 578 jobs targeted.
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.